Skip to main content

5 Result(s)

within Takahiro Ebata Remove this filter Medicine & Public Health Remove this filter Cancer Research Remove this filter

and

  1. No Access

    Article

    A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors

    Combination treatment using lenvatinib (a multikinase inhibitor) plus pembrolizumab (a programmed death-1 immune checkpoint inhibitor) has shown efficacy in the treatment of endometrial and renal cell cancers....

    Shigehisa Kitano, Yutaka Fujiwara, Toshio Shimizu… in Cancer Chemotherapy and Pharmacology (2022)

  2. Article

    Open Access

    Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

    Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced mali...

    Shigehisa Kitano, Toshio Shimizu, Takafumi Koyama… in Cancer Chemotherapy and Pharmacology (2021)

    Download PDF (2400 KB) View Article

  3. No Access

    Article

    Improved survival among patients enrolled in oncology phase 1 trials in recent decades

    This study aimed to compare the survival of patients enrolled in phase 1 trials in recent decades.

    Takahiro Ebata, Toshio Shimizu, Takafumi Koyama… in Cancer Chemotherapy and Pharmacology (2020)

  4. No Access

    Article

    Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study

    The purpose of this study was to evaluate the real world situation and clarify the problem in initial treatment for elderly patients with ovarian cancer in Japan.

    Seiko Bun, Mayu Yunokawa, Takahiro Ebata… in International Journal of Clinical Oncology (2019)

  5. No Access

    Article

    Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer

    Weekly dose-dense paclitaxel (PTX) in combination with carboplatin (CBDCA) every 3 weeks (ddTC therapy) is a standard treatment for patients with advanced ovarian cancer. However, there is no detailed analysis...

    Seiko Bun, Mayu Yunokawa, Takahiro Ebata… in Cancer Chemotherapy and Pharmacology (2016)